Sanofi has backed the $75 million series B of a rhinovirus-focused biotech with a former FDA acting commissioner at the helm. | Sanofi has backed the $75 million series B of a rhinovirus-focused ...

Altesa BioSciences, a clinical-stage pharmaceutical company dedicated to improving the lives of people with chronic lung diseases including COPD and asthma, today announced a $75 million ...

Please provide your email address to receive an email when new articles are posted on . More than a quarter of children with refractory wheeze were positive for rhinovirus despite a lack of symptoms.

Rhinovirus infections may ramp up genes that help the lung airway defend itself against SARS-CoV-2. In this study, participants with a rhinovirus infection in the previous 30 days had a 48% lower risk ...

During the height of the pandemic, COVID-19 restrictions caused a drop in cases of other respiratory viruses, like rhinovirus. But now, it seems, rhinovirus is back in a big way. The virus, which ...

Using a laboratory model of the human nose, scientists have investigated why the severity of common-cold infections varies so widely between individuals.

September 16, 2010 (Boston, Massachusetts) — Despite expectations to the contrary, the use of a hand disinfectant did not achieve significant protection against transmission of rhinovirus-associated ...

Rhinoviruses cause serious morbidity and mortality as the major etiological agents of asthma exacerbations and the common cold. A major obstacle to understanding disease pathogenesis and to the ...